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Edited by Barry HalliwellAbstract Evidence has accumulated that some of the angioten-
sin II AT1 receptor antagonists have insulin-sensitizing property.
We thus examined the eﬀect of telmisartan on insulin action
using 3T3-L1 adipocytes. With standard diﬀerentiation inducers,
a higher dose of telmisartan eﬀectively facilitated diﬀerentiation
of 3T3-L1 preadipocytes. Treatment of both diﬀerentiating
adipocytes and fully diﬀerentiated adipocytes with telmisartan
caused a dose-dependent increase in mRNA levels for PPARc
target genes such as aP2 and adiponectin. By contrast, telmi-
sartan attenuated 11b-hydroxysteroid dehydrogenase type 1
mRNA level in diﬀerentiated adipocytes. Of note, we demon-
strated for the ﬁrst time that telmisartan augmented GLUT4
protein expression and 2-deoxy glucose uptake both in basal and
insulin-stimulated state of adipocytes, which may contribute, at
least partly, to its insulin-sensitizing ability.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Functional abnormalities in adipocytes have been implicated
in the pathophysiology of type 2 diabetes and the metabolic
syndrome [1]. Peroxisome proliferator-activated receptor c
(PPARc), a nuclear receptor abundantly expressed in adipo-
cytes, plays a pivotal role in adipocyte diﬀerentiation, function
and distribution through regulating a wide variety of target
genes [2]. Actually, synthetic ligands for PPARc, thiazolidin-
edione derivatives (TZDs), have proven to be eﬀective for the
treatment of insulin resistance and diabetes in humans [3,4].
Although TZDs such as pioglitazone [5] and rosiglitazone [6]
are widely employed in clinical practice, in some cases, these
compounds cause adverse eﬀects such as ﬂuid retention, pe-
ripheral edema and heart failure [7].
A number of clinical trials have suggested that angiotensin-
converting enzyme inhibitors or angiotensin II AT1 receptor
antagonists (or angiotensin II receptor blockers, ARBs) can* Corresponding author. Fax: +81-75-771-9452.
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doi:10.1016/j.febslet.2004.09.027improve insulin sensitivity and signiﬁcantly reduce the inci-
dence of newly occurred type 2 diabetes in patients with hy-
pertension [8,9]. However, the mechanism whereby blockade
of renin–angiotensin system enhances whole body insulin
sensitivity has not been fully elucidated so far [10,11]. Very
recently, it has been reported that a clinically used ARB, tel-
misartan, shares a structural similarity with pioglitazone and
can serve as a partial agonist of PPARc [12,13]. The work
demonstrated that telmisartan uniquely augmented the ex-
pression of established PPARc target genes including aP2
(FABP4), CD36, and acetyl coenzyme A carboxylase (ACC) in
murine and human adipocytes and murine myocytes [12] as
well as induced adipogenesis in 3T3-L1 preadipocytes [12].
Furthermore, data have shown that orally-administered tel-
misartan improved glucose and lipid homeostasis in rats fed
high-fat and high-carbohydrate diet [12]. However, underlying
mechanism responsible for insulin-sensitizing eﬀects by telmi-
sartan has not been fully addressed. Moreover, systemic ad-
ministration experiments would not be enough to clarify the
exact action site of telmisartan in terms of improvement of fuel
homeostasis.
In this context, the present study was designed to elucidate
the eﬀect of telmisartan on insulin action using 3T3-L1
adipocytes. We here show that telmisartan coordinately regu-
lates mRNA expression of insulin-sensitizing hormone,
adiponectin [14,15] and insulin resistance-inducing enzyme,
11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) [16,17],
which may favor adipocytes with insulin sensitization. We also
demonstrate for the ﬁrst time that telmisartan augments
GLUT4 protein expression and 2-deoxy glucose uptake in
3T3-L1 adipocytes, providing evidence that telmisartan exerts
its insulin-sensitizing eﬀects directly on adipocytes.2. Materials and methods
2.1. Materials
Angiotensin II AT1 receptor antagonists, telmisartan (BIBR 277)
and valsartan (CGP 48933), and a thiazolidinedione derivative, piog-
litazone (AD-4833), were generously provided from Nippon Boehrin-
ger Ingelheim (Tokyo, Japan), Novartis Pharma (Tokyo, Japan) and
Takeda Chemical Industries (Osaka, Japan), respectively. Human re-
combinant insulin was purchased from Roche Diagnostics (Tokyo,
Japan). 3-Isobutyl-1-methylxanthine (IB) and dexamethasone (DX)blished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀect of telmisartan on adipose diﬀerentiation of 3T3-L1 cells.
Telmisartan, valsartan and pioglitazone were dissolved in DMSO
(vehicle) and added to media from the start of diﬀerentiation (day 0) to
mature adipocyte (day 8). (A) Diﬀerentiated adipocytes were ﬁxed and
stained with Oil Red O at day 8. Macroscopic and microscopic pictures
(magnitude 50) of cells are shown. (B) Lipid accumulation was as-
sessed by the quantiﬁcation of OD510 in destained Oil Red O with
isopropanol. Telmisartan signiﬁcantly facilitated adipogenesis in a
concentration of 1 lM (17 6% increase) and 10 lM (17 5% in-
crease). Data are expressed as meansS.E.M. from triplicate experi-
ments. **P < 0:01 (Student’s t test) compared with vehicle (V) treated
group. Pio: pioglitazone.
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Modiﬁed Eagle’s Medium (DMEM), Calf Serum (CS) and Fetal Bo-
vine Serum (FBS) were from Invitrogen Corp. (Carlsbad, CA, USA).
ECL plus western detecting kit was purchased from Amersham Bio-
sciences Corp. (Piscataway, NJ, USA).
2.2. Cell culture and Oil Red O staining
3T3-L1 cells (kindly provided by Dr. H. Green and Dr. M. Mor-
ikawa, Harvard Medical School, Boston, MA, USA) were cultured
and diﬀerentiated into adipocytes as described previously [18]. Brieﬂy,
cells were grown for 2 days post-conﬂuence (referred as day 0) in 10%
CS/DMEM. Diﬀerentiation was induced with 10% FBS/DMEM con-
taining 0.5 mM IB, 0.25 lM DX and 1 lg/ml insulin for 2 days. The
cells were then incubated in 10% FBS/DMEM with insulin for 2 days
and maintained hereafter with 10% FBS/DMEM to day 8. Telmisar-
tan, valsartan and pioglitazone were dissolved in DMSO and added to
media within 0.1% of volume. Medium was changed every other day.
At day 8, the cells were washed with PBS twice, ﬁxed in 3.7% form-
aldehyde for 1 h and then stained with 0.6% (w/v) Oil Red O solution
(60% isopropanol, 40% water) for 2 h at room temperature. Cells were
then washed with water to remove unbound dye. Stained Oil Red O
was eluted with isopropanol and quantiﬁed by measuring the optical
absorbance at 510 nm [19].
2.3. Northern blot analyses and quantitative real time PCR
During the course of adipose diﬀerentiation, all compounds in-
cluding DMSO (vehicle) were added to media on day 2 (diﬀerentiating
state) or on day 8 (mature adipocyte) for 24 h. Although insulin was
added to media from day 2 to day 3, media without insulin were used
in case of extracting RNA on day 3. After 24 h incubation, total RNA
of 3T3-L1 cells was prepared using Trizol Reagent (Invitrogen). To
determine mouse aP2 and adiponectin mRNA expression levels, equal
amount of total RNA (20 lg/each lane) was electrophorased, trans-
ferred and Northern blot hybridization was performed as described
previously [20]. For quantitative RT-PCR assay, cDNA was prepared
from total RNA using SuperScript First-Strand Synthesis System
(Invitrogen). To determine 11b-HSD1 mRNA levels, these probe and
primers were employed [21]: probe (50FAM-cgtcatctcctccttggctgggaa-
TAMRA-30), forward (50-agcagagcaatggcagcat-30) and reverse (50-
gagcaatcataggctgggtca-30). TaqMan PCR was performed using ABI
Prism 7700 Sequence Detection System as instructed by manufacturer
(Applied Biosystems, Foster City, CA, USA). Results were normalized
to endogenous control 18S mRNA concentrations.
2.4. Western blot analyses
Cells were washed twice with ice-cold PBS and harvested in a lysis
buﬀer (10 mM Tris–HCl, 1 mM EDTA, 255 mM sucrose, 1% (v/v)
Nonidet P-40, 1 mM PMSF and 0.1 mg/ml aprotinin at pH 7.4). After
centrifugation, supernatants were normalized for protein concentra-
tion via Bradford method and subjected to immunoblotting. Western
blot analyses were performed using anti-polyclonal GLUT4 antibody
(Santa Cruz Biotechnology, California, CA, USA) as reported previ-
ously [22].
2.5. 2-Deoxy glucose uptake assay
Cells were treated with 0.1% DMSO, telmisartan, valsartan or
pioglitazone throughout the course of diﬀerentiation. On day 8, glu-
cose transport by monolayer of 3T3-Ll adipocytes was assessed by the
uptake of 2-deoxy-L-[3H]glucose (Perkin Elmer Life Sciences, Boston,
MA, USA) as reported previously [20].
2.6. Statistical analyses
The data are presented as means S.E.M. Student’s t test was used
to compare the data between the vehicle (DMSO) and treated group.
Diﬀerences were accepted as signiﬁcant at P < 0:05 level.3. Results
3.1. Telmisartan facilitates lipid accumulation in 3T3-L1
adipocytes
To explore the potential eﬀect of telmisartan on adipogen-
esis, 3T3-L1 preadipocytes were diﬀerentiated with telmisartan
in addition to standard diﬀerentiation inducers (i.e., IB, DXand insulin) [18]. As shown in Fig. 1, higher doses (1 and 10
lM) of telmisartan facilitated diﬀerentiation of 3T3-L1 cells,
whereas a lower dose (0.1 lM) did not. On the contrary, val-
sartan had no eﬀect on adipogenesis even with a concentration
of 10 lM. These data were well in agreement with previous
report [12]. Also, consistent with previous reports [23,24],
pioglitazone facilitated the diﬀerentiation of preadipocytes
with a concentration of 1 lM.
3.2. Telmisartan regulates a line of PPARc target genes
To elucidate regulation of PPARc downstream genes by
telmisartan in adipocytes, compounds were added to diﬀer-
entiation media on day 2 (Fig. 2) or on day 8 (Fig. 3) for 24 h.
By addition of 10 lM telmisartan from day 2 to day 3 (dif-
ferentiating state), mRNA levels of aP2 and adiponectin were
increased about 2.4 0.1-fold (P < 0:01) and 2.2 0.1-fold
(P < 0:01) compared to vehicle (DMSO) treatment, respec-
tively (Fig. 2A and B). Noteworthy is that such an increase in
Fig. 3. Telmisartan regulates PPARc target genes in diﬀerentiated
3T3-L1 adipocytes (day 9). Cells were diﬀerentiated to mature adi-
pocyte (day 8) and treated with compounds for 24 h. Northern blot
analyses of aP2 (A) and adiponectin (B) were performed. Quantiﬁ-
cation of relative mRNA expression was shown. (C) Speciﬁc mRNA
for 11b-HSD1 was determined by quantitative RT-PCR. Results were
normalized to the signal generated from 18S mRNA. Data are ex-
pressed as meansS.E.M. from quadruplicate (aP2 and adiponectin)
or triplicate (11b-HSD1) experiments. **P < 0:01 (Student’s t test)
compared with vehicle (V) treated group. Adipo: adiponectin, Pio:
pioglitazone.
Fig. 2. Telmisartan regulates PPARc target genes in diﬀerentiating
3T3-L1 cells (day 3). Cells were diﬀerentiated and treated with com-
pounds on day 3 for 24 h. Total RNA was extracted and Northern blot
analyses of aP2 (A) and adiponectin (B) were performed. Quantiﬁca-
tion of relative mRNA expression was shown. (C) Speciﬁc mRNA for
11b-HSD1 was determined by quantitative RT-PCR. Results were
normalized to the signal generated from 18S mRNA. Data are ex-
pressed as means S.E.M. from quadruplicate (aP2 and adiponectin)
or triplicate (11b-HSD1) experiments. *P < 0:05, **P < 0:01 (Stu-
dent’s t test) compared with vehicle (V) treated group. Adipo: adipo-
nectin, Pio: pioglitazone.
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hand, valsartan did not augment mRNA expression of aP2
and adiponectin. The level of mRNA for 11b-HSD1, which
has been shown to increase by 500-fold during diﬀerentiation
of 3T3-L1 cells [25], was not changed by telmisartan, valsartan
or pioglitazone (Fig. 2C).
When ARBs were added to media after cells were diﬀeren-
tiated into adipocytes, aP2 and adiponectin mRNA levels werealso elevated only by 10 lM telmisartan (2.2 0.1-fold
(P < 0:01) and 2.1 0.1-fold (P < 0:01), respectively), whereas
valsartan did not exert such eﬀects (Fig. 3A and B). In diﬀer-
entiated adipocytes, gene expression of 11b-HSD1, known to
be downregulated by PPARc ligand [25], was signiﬁcantly
decreased by 10 lM telmisartan (0.6 0.1-fold (P < 0:01)), but
not by valsartan (Fig. 3C).
Fig. 5. Telmisartan signiﬁcantly increases GLUT4 protein expression
in 3T3-L1 adipocytes. Cells were treated with compounds throughout
the course of diﬀerentiation. On day 8, total cell lysates were prepared
and equal amount of protein (5 lg) was subjected to Western blotting.
Quantiﬁcation of relative protein expression was plotted. Data are
presented as meanS.E.M. from triplicate experiments. *P < 0:05,
**P < 0:01 (Student’s t test) compared with vehicle (V) treated group.
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3T3-L1 adipocytes
To examine a potential impact of telmisartan on glucose
transport in diﬀerentiated 3T3-L1 adipocytes, 2-deoxy glucose
(2-DG) uptake assay was performed. Although treatment with
valsartan did not aﬀect 2-DG uptake even with a concentra-
tion of 10 lM, telmisartan signiﬁcantly increased glucose up-
take. Even in the absence of insulin (Fig. 4A), 1 and 10 lM
telmisartan signiﬁcantly augmented 2-DG uptake in adipo-
cytes by 1.9 0.2-fold (P < 0:05) and 3.0 0.2-fold (P < 0:01),
respectively. In the presence of 1 lM insulin (Fig. 4B), 1 and 10
lM telmisartan also signiﬁcantly augmented glucose uptake
by 1.7 0.2-fold (P < 0:05) and 2.7 0.5-fold (P < 0:01),
respectively.
3.4. Telmisartan increases GLUT4 protein level in 3T3-L1
adipocytes
Based on our result that telmisartan has a robust eﬀect on
glucose uptake, we next assessed its impact on GLUT4 protein
expression. Western blot analyses showed that, when cells were
diﬀerentiated with 1 or 10 lM of telmisartan, GLUT4 protein
was signiﬁcantly increased compared to DMSO treatmentFig. 4. Telmisartan increases glucose transport in 3T3-L1 adipocytes.
Cells were treated with compounds throughout the course of adipocyte
diﬀerentiation (day 0–day 8). 2-DG uptake was measured in the ab-
sence (A) or presence (B) of 1 lM insulin. Telmisartan signiﬁcantly
augmented 2-DG uptake in a dose-dependent manner. Data are pre-
sented as meansS.E.M. from quadruplicate experiments. *P < 0:05,
** P < 0:01 (Student’s t test) compared with vehicle (V) treated group.
Pio: pioglitazone.
Pio: pioglitazone.(1.4 0.1-fold, or 1.3 0.1-fold, P < 0:05, respectively)
(Fig. 5). In contrast, valsartan did not augment GLUT4 pro-
tein expression even with a concentration of 10 lM.4. Discussion
We here demonstrate that telmisartan dose-dependently
augments GLUT4 protein expression and 2-deoxy glucose
uptake both in basal and insulin-stimulated state of 3T3-L1
adipocytes. The potency of such insulin-sensitizing eﬀects is
comparable to that seen in pioglitazone-treated cells and is not
observed in cells treated with valsartan. To the best of our
knowledge, this is the ﬁrst report providing evidence that tel-
misartan exerts its insulin-sensitizing eﬀects directly on
adipocytes. Consistent with our data, previous reports have
shown that TZDs augment GLUT4 protein expression and
glucose uptake in cultured adipocytes [23,24,26,27]. Although
several mechanisms are involved in the molecular control of
GLUT4 expression by TZDs [28–30], the result allows us to
speculate that telmisartan induces GLUT4 expression and
subsequent glucose uptake, at least in part, via PPARc acti-
vation in adipocytes.
A line of evidence has suggested that the activation of the
renin–angiotensin system impairs early steps of insulin recep-
tor signaling such as tyrosine phosphorylation of insulin re-
ceptor substrate 1 or activation of PI3-kinase both in vivo and
in vitro [31,32]. On the other hand, it has been shown that
chronic angiotensin II receptor antagonism via clinically em-
ployed ARB, irbesartan increases muscle GLUT4 protein
levels in Zucker fatty (fa/fa) rats [33]. Taken together, it is
tempting to speculate that the blockade of angiotensin II re-
ceptor signaling might exert metabolically beneﬁcial eﬀects in
adipocytes. Nevertheless in skeletal muscle of type 2 diabetic
mouse, valsartan has been shown to enhance GLUT4 trans-
location to plasma membrane [34], no reports have shown that
ARBs increase GLUT4 protein expression and subsequent
496 M. Fujimoto et al. / FEBS Letters 576 (2004) 492–497glucose uptake in adipocytes. In this context, our data provide
evidence that telmisartan is the case.
It has been widely recognized that PPARc expressing in
‘‘extra-adipose’’ tissues such as macrophage, colon, liver,
skeletal muscle, pancreatic b cells or pituitary cells is also in-
volved in a line of pathologic conditions including type 2 di-
abetes, steatosis, atherosclerosis and cancer [35,36]. Moreover,
angiotensin II AT1 receptor has been shown to express in a
wide variety of tissues including adipocytes [37–39]. Thus, an
entire picture of the in vivo mechanism whereby telmisartan
improves glucose homeostasis must await further investiga-
tion. However, our results suggest that adipocytes are one
of the major sites of action for telmisartan in terms of fuel
metabolism.
A growing body of evidence has suggested that PPARc
agonists have the strong potential to correct functional ab-
normalities in adipocytes including amelioration of dysregu-
lation in adipocytokine release (see [1] for review). A prototype
of adipocytokines, adiponectin, has been recognized as a fat-
cell derived insulin-sensitizing hormone [14,15]. Our data
demonstrate that, in both diﬀerentiating and diﬀerentiated
3T3-L1 adipocytes, telmisartan augments mRNA expression
of adiponectin in a dose-dependent manner, which may also
contribute to metabolically-beneﬁcial eﬀects of telmisartan.
Furthermore, the present study demonstrates that, in dif-
ferentiated adipocytes, telmisartan substantially decreases
mRNA level for 11b-HSD1, an intracellular glucocorticoid
reactivating enzyme [16,17]. Evidence has accumulated that
locally-enhanced action of glucocorticoid in adipocytes, med-
iated by exaggerated activation of 11b-HSD1, plays an im-
portant role in adipocyte dysfunction and adipocytokine
dysregulation [16,17,40,41]. Taken together, it is reasonable to
speculate that telmisartan-induced decrease in the mRNA level
for 11b-HSD1 favors adipocytes with insulin sensitization. It is
known that gene expression of 11b-HSD1 is markedly induced
( by 500-fold) during the course of adipose diﬀerentiation
[25], which may explain, at least in part, why we failed to
observe the decrease in mRNA level for 11b-HSD1 by telmi-
sartan in diﬀerentiating adipocytes.
In summary, the present study ﬁrst provides evidence that
telmisartan enhances glucose uptake in cultured adipocytes,
accompanied by an increase in GLUT4 expression. Coordi-
nated regulation of mRNA expressions for adiponectin and
11b-HSD1 in adipocytes may also be beneﬁcial for insulin-
sensitizing eﬀects by telmisartan. Our data provide a fresh
insight into improved therapeutic approaches to treat type 2
diabetes, hypertension with insulin resistance and the meta-
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